INT83288

Context Info Confidence 0.51 First Reported 1999 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 12 Total Number 12 Disease Relevance 3.58 Pain Relevance 0.28

mitochondrion (NEU4) small molecule metabolic process (NEU4) hydrolase activity, acting on glycosyl bonds (NEU4) lysosome (NEU4)

NEU4 (Homo sapiens)

Pain Link Frequency Relevance Heat headache 4 100.00 fibrosis 3 78.24 cINOD 5 75.28 Bioavailability 5 64.88 Analgesic 4 25.00 antidepressant 14 5.00 corticosteroid 12 5.00 Gabapentin 8 5.00 COX-2 inhibitor 6 5.00 sSRI 6 5.00

Disease Link Frequency Relevance Heat Influenza Virus Infection 139 100.00 Influenza In Birds 38 95.84 Viral Infection 2 94.76 Infection 64 94.60 Emerging Communicable Diseases 1 88.52 Pseudomonas Infection 3 87.92 Disease 34 80.32 Cystic Fibrosis 3 78.80 Thalassemia 2 77.40 Thyroid Crisis 1 69.56

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Neuraminidase (NA) inhibitors are the most promising agents despite uncertainty about efficacy.

Negative_regulation (inhibitors) of Neuraminidase

1) Confidence 0.51 Published 2007 Journal Med. Microbiol. Immunol. Section Abstract Doc Link 17431677 Disease Relevance 0.52 Pain Relevance 0.08

Neuraminidase inhibitors: zanamivir and oseltamivir.

Negative_regulation (inhibitors) of Neuraminidase associated with headache

2) Confidence 0.43 Published 2001 Journal Ann Pharmacother Section Title Doc Link 11197587 Disease Relevance 0 Pain Relevance 0.10

If used appropriately to minimize the development of resistance, the neuraminidase inhibitors represent a new and unique class of antiinfluenza agents that can potentially reduce the morbidity associated with influenza.

Negative_regulation (inhibitors) of neuraminidase

3) Confidence 0.43 Published 2001 Journal Ann Pharmacother Section Body Doc Link 11197587 Disease Relevance 0 Pain Relevance 0

OBJECTIVE: Oseltamivir is the only oral neuraminidase inhibitor currently available; we determined the tolerability and antiviral efficacy of oral peramivir for treatment and prophylaxis of experimental human influenza A and B.

Negative_regulation (inhibitor) of neuraminidase associated with influenza virus infection

4) Confidence 0.43 Published 2005 Journal Antivir. Ther. (Lond.) Section Abstract Doc Link 16430195 Disease Relevance 0.17 Pain Relevance 0

Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication.

Negative_regulation (inhibits) of neuraminidase associated with influenza virus infection

5) Confidence 0.14 Published 2010 Journal Journal of Antimicrobial Chemotherapy Section Abstract Doc Link PMC2835511 Disease Relevance 0.42 Pain Relevance 0.03

Tamiflu is an NAI that was rationally designed to inhibit the influenza A and B neuraminidase; however, there is a basis for considering that a neuraminidase present in a bacterium could also be inhibited by Tamiflu.

Negative_regulation (inhibit) of neuraminidase associated with influenza virus infection

6) Confidence 0.08 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2592279 Disease Relevance 0.55 Pain Relevance 0.03

The highest priority knowledge gaps identified by participants fell into four main areas: a) ecotoxicologic effects; b) antiviral resistance; c) STP failure, particularly as a result of nontarget neuraminidase inhibition (e.g., microorganisms); and d) exposure models to define realistic worst-case scenarios for environmental exposure.

Negative_regulation (inhibition) of neuraminidase

7) Confidence 0.08 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2592279 Disease Relevance 0 Pain Relevance 0

Tamiflu is an NAI that was rationally designed to inhibit the influenza A and B neuraminidase; however, there is a basis for considering that a neuraminidase present in a bacterium could also be inhibited by Tamiflu.

Negative_regulation (inhibited) of neuraminidase associated with influenza virus infection

8) Confidence 0.08 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2592279 Disease Relevance 0.60 Pain Relevance 0.04

In contrast to clade 1 H5N1 viruses isolated in Vietnam and clade 2.1 viruses in Indonesia [2], the clade 2.3.4 and clade 2.2 H5N1 viruses isolated from cases in China were susceptible to both M2 inhibitors and neuraminidase inhibitors (unpublished data, China CDC).

Negative_regulation (inhibitors) of neuraminidase

9) Confidence 0.06 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515635 Disease Relevance 0.23 Pain Relevance 0

The BMJ and Channel 4 News reported on the difficulties in obtaining data for an updated Cochrane review on neuraminidase inhibitors in influenza [129].

Negative_regulation (inhibitors) of neuraminidase associated with influenza virus infection

10) Confidence 0.04 Published 2010 Journal Trials Section Body Doc Link PMC2867979 Disease Relevance 0.75 Pain Relevance 0

OBJECTIVE: The objective of this study was to assess the potential of zanamivir, a specific inhibitor of influenza A and B virus neuraminidase, to interact with other coadministered therapies in the clinical setting.

Negative_regulation (inhibitor) of neuraminidase associated with influenza virus infection

11) Confidence 0.04 Published 1999 Journal Clin Pharmacokinet Section Abstract Doc Link 10429839 Disease Relevance 0.10 Pain Relevance 0

As published evidence on other combination chemotherapies is currently lacking, the study will also investigate the activity of oseltamivir when used in combination with zanamivir, a second neuraminidase inhibitor.

Negative_regulation (inhibitor) of neuraminidase

12) Confidence 0.02 Published 2010 Journal Journal of Antimicrobial Chemotherapy Section Body Doc Link PMC2835509 Disease Relevance 0.23 Pain Relevance 0

General Comments

This test has worked.